Deal Details
Crinetics Completes $350.1 Million Follow-On Offering
Summary
Crinetics Pharmaceuticals, Inc. (“Crinetics”) (NASDAQ: CRNX) recently completed an underwritten public offering (the “Offering”) of 7,620,000 of its common stock at a price of $45.95 per share, generating gross proceeds of approximately $350.1 million. Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1,143,000 shares of its common stock. Crinetics intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and investment securities, to fund its commercial activities in connection with the launch of PALSONIFY™, research and development of its product candidates, other research programs and other general corporate purposes. Crinetics may also use a portion of the remaining net proceeds to in-license, acquire or invest in complementary businesses, technologies, products or assets.
Baird served as a lead manager on this Offering.
Baird served as a lead manager on this Offering.
About
Crinetics is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors with small molecules that have specifically tailored pharmacology and properties. Crinetics is headquartered in San Diego, California.CONTACT US TO LEARN MORE
- Date
- January 2026
- Company
- Crinetics Pharmaceuticals, Inc.
- Transaction
- Equity Capital Markets
- Sectors
- Healthcare
- Verticals
-
Biotechnology & Pharmaceuticals
- Target Geography
- North America
Share
